Clinical Trial Detail

NCT ID NCT02474355
Title Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

Age Groups: adult

No variant requirements are available.